Candel Therapeutics, Inc. CADL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s total equity?
- Candel Therapeutics, Inc. (CADL) reported total equity of $138.03M in Q1 2026.
- How has Candel Therapeutics, Inc.'s total equity changed year-over-year?
- Candel Therapeutics, Inc.'s total equity increased by 84.8% year-over-year, from $74.68M to $138.03M.
- What is the long-term trend for Candel Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s total equity has grown at a 17.1% compound annual growth rate (CAGR), from -$23.56M to $51.92M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.